Specifically, we revealed that DOCK1 inhibition by shRNAs or TBOPP, a DOCK1 selective inhibitor, suppressed metformin-induced RAC1 activation, thus enhancing the anti-tumor effects of metformin in both patient-derived organoids and mouse models of liver cancer. The gene discussed is RAC1; the disease is neoplasm.